Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare wit...

Full description

Bibliographic Details
Main Authors: Antoine Deleuze, Judikaël Saout, Frédéric Dugay, Benoit Peyronnet, Romain Mathieu, Gregory Verhoest, Karim Bensalah, Laurence Crouzet, Brigitte Laguerre, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq, Solène-Florence Kammerer-Jacquet
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:International Journal of Molecular Sciences
Subjects:
immunotherapy
immune checkpoint inhibitors
renal cell carcinoma
PD-1
PD-L1
ongoing trials
Online Access:https://www.mdpi.com/1422-0067/21/7/2532

Internet

https://www.mdpi.com/1422-0067/21/7/2532

Similar Items